Please ensure Javascript is enabled for purposes of website accessibility

3 Top Pharma Stocks to Buy in April

By Keith Speights – Updated Apr 11, 2020 at 12:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The time is right and the price is right to buy these big pharma stocks.

In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different. 

Because of the coronavirus pandemic and the subsequent stock market plunge, this month is a very good time to invest in stocks. I'd argue that it's an especially great time to invest in shares of big drugmakers. Many pharma stocks have been hammered much harder than is warranted. My view is that three pharma stocks stand out as the top picks to buy in April.

Multicolored pills forming a dollar sign

Image source: Getty Images.

1. AbbVie

There's one overwhelmingly compelling argument for buying shares of AbbVie (ABBV -2.12%). The drugmaker's dividend yields 6%. Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future.

Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. It's increased the dividend payout for a remarkable 47 consecutive years. And since being spun off from Abbott in 2013, AbbVie's dividend has nearly tripled.

Can AbbVie keep the dividends flowing and growing? I think so. Sales continue to soar for the company's cancer drugs Imbruvica and Venclexta. AbbVie's new immunology drugs Rinvoq and Skyrizi are expected to become megablockbusters over the next few years. The drugmaker's pending acquisition of Allergan will bring successful products including Botox and antipsychotic drug Vraylar into its lineup.

The primary headwind for AbbVie is the loss of exclusivity for its top-selling drug Humira in Europe, with the prospects of biosimilar competition in the U.S. only three years away. However, AbbVie should be able to offset the sales declines for Humira with its current products, promising pipeline candidates, and the addition of Allergan. The company might not deliver awe-inspiring earnings growth, but with its tremendous dividend, it doesn't need to in order for investors to still enjoy solid total returns.

2. Bristol Myers Squibb

If you're looking for great growth prospects in addition to a nice dividend, check out Bristol Myers Squibb (BMY -0.95%). The big drugmaker's dividend yield stands at more than 3%, which isn't too shabby at all. But I think that BMS is poised to generate impressive growth over the next few years.

It certainly helps that BMS claims two of the drugs that market researcher EvaluatePharma projects will rank in the top five best-selling blockbusters in the world by 2024 -- blood thinner Eliquis and cancer immunotherapy Opdivo. BMS also has a couple of rising stars with arthritis drug Orencia and multiple myeloma drug Empliciti.

But the acquisition of Celgene in November 2019 was a game changer for Bristol Myers Squibb. The company's lineup now includes blockbuster blood cancer drugs Revlimid and Pomalyst, along with solid tumor drug Abraxane. And thanks to the Celgene deal, BMS also now has recently approved drugs Reblozyl and Zeposia that have blockbuster-sales potential.

More winners should be on the way. Celgene's pipeline was loaded with great candidates that BMS now has. The most promising of these include cell therapies ide-cel and liso-cel. Wall Street analysts project that BMS will grow its earnings by an average of more than 18% annually over the next five years. With this kind of growth plus its attractive valuation and strong dividend, Bristol Myers Squibb appears to be a no-brainer big pharma stock to buy in April.

3. Pfizer

Pfizer (PFE -2.33%) is a good pick to buy right now for investors who want to get ahead of what's on the way. I'm referring to Pfizer's plan to spin off its Upjohn unit and merge it with Mylan (MYL) to form a new company that will be named Viatris. Although the COVID-19 pandemic has caused Pfizer to delay the transaction, it's still set to wrap up later this year.

My view is that Pfizer will be set to deliver growth that's better than most big pharma companies once the Upjohn-Mylan deal finalizes. The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel. 

The company's pipeline also includes eight programs awaiting regulatory approvals and over 20 programs in late-stage clinical studies. I'm especially optimistic about the prospects for pneumococcal vaccine PF-06482077.

Pfizer's dividend currently yields close to 4.4%. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend. 

Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$43.09 (-2.33%) $-1.03
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$70.24 (-0.95%) $0.67
AbbVie Inc. Stock Quote
AbbVie Inc.
$140.29 (-2.12%) $-3.04
Mylan Stock Quote
Allergan Stock Quote
Abbott Laboratories Stock Quote
Abbott Laboratories
$102.45 (-0.90%) $0.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.